GenMark Diagnostics, Inc.·4

Jan 22, 6:25 PM ET

Maderazo Alan Baer 4

4 · GenMark Diagnostics, Inc. · Filed Jan 22, 2021

Insider Transaction Report

Form 4
Period: 2021-01-20
Maderazo Alan Baer
VP, Qual, Reg, & Clin Affairs
Transactions
  • Sale

    Common Stock

    2021-01-20$15.00/sh5,000$75,000225,899 total
  • Exercise/Conversion

    Common Stock

    2021-01-21+21,694274,418 total
  • Exercise/Conversion

    Common Stock

    2021-01-21+16,666291,084 total
  • Exercise/Conversion

    Market Stock Units

    2021-01-2121,6946,667 total
    Exercise: $0.00Common Stock (21,694 underlying)
  • Exercise/Conversion

    Common Stock

    2021-01-21+26,825252,724 total
  • Exercise/Conversion

    Market Stock Units

    2021-01-2126,8250 total
    Exercise: $0.00Common Stock (26,825 underlying)
  • Exercise/Conversion

    Market Stock Units

    2021-01-2116,66616,667 total
    Exercise: $0.00Common Stock (16,666 underlying)
Footnotes (5)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by reporting person on 7/28/2020.
  • [F2]The MSU's vest in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third performance periods, the Reporting Person was eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares on the Issuer's three-year total Shareholder return, as compared to the Nasdaq Composite Index.
  • [F3]The MSU's vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares on the Issuer's two-year total Shareholder return, as compared to the Nasdaq Composite Index.
  • [F4]Represents the target number of shares which remain subject to the award.
  • [F5]The MSU's vest in three equal installments, on each of December 31, 2020, December 31, 2021, and December 31, 2022; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares on the Issuer's one-year total Shareholder return, as compared to the Nasdaq Composite Index.

Documents

1 file
  • 4
    wf-form4_161135793753010.xmlPrimary

    FORM 4